biovision nec 1s

MMP9 accumulation and increased tropoelastin and lysyl oxidase aortic levels

Abstract
Abdominal aortic aneurysm (AAA) is a common aortic disease with a progressive nature. There is no approved pharmacological treatment that would effectively slow the growth of the aneurysm or prevent rupture. Necrosis is a form of programmed necrosis that is regulated by receptor-interacting protein kinases (RIPs). We have recently shown that a lack of RIP3 in mice prevented aneurysm formation.

The aim of this study is to test whether disruptive necrosis affects the progression of existing aneurysms using RIP1 inhibitors Necrostatin-1 (Nec-1) and optimized forms of Nec-1, 7-Cl-O-Nec-1 (Nec-1 s). Seven days after induction of the aneurysm by elastase perfusion, mice were randomly administered DMSO, Nec-1 (3.2 mg / kg / day) and Nec-1s (1.6 mg / kg / day) by intraperitoneal injection. After sacrifice on day 14 of postaneurysm induction, the aortic expansion in the Nec-1s group (64.12 ± 4.80%) was significantly smaller than in the DMSO group (172.80 ± 13.68%) (P <0.05).

Product Details:

Alternate Name5-((7-Cl-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dione); 7-Cl-O-Nec-1
Peptide SequenceNo
AppearanceYellow solid
CAS #852391-15-2
Molecular FormulaC₁₃H₁₂ClN₃O₂
Molecular Weight277.71
Purity≥96% by TLC and LC-MS
SolubilityDMSO
SMILESCN1C(=O)C(NC1=O)CC2=CNC3=C2C=CC=C3Cl
InChiInChI=1S/C13H12ClN3O2/c1-17-12(18)10(16-13(17)19)5-7-6-15-11-8(7)3-2-4-9(11)14/h2-4,6,10,15H,5H2,1H3,(H,16,19)
InChi KeyWIKGAEMMNQTUGL-UHFFFAOYSA-N
PubChem CID643953
HandlingProtect from light and moisture
Storage Conditions-20°C
Shipping ConditionsGel Pack
USAGEFor Research Use Only! Not For Use in Humans.
biovision nec 1s

biovision nec 1s

 

Descriptions:

A potent necroptosis inhibitor. Displays higher activity in inhibiting necroptosis in Jurkat cells than Nec-1 (Cat. No. 1864) (EC₅₀ = 210 nM versus EC₅₀ = 490 nM), as well as showing no nonspecific cytotoxicity at high concentrations (~100 mM). More useful for in-cell and in vivo experiments compared to Nec-1.

 

The mean aortic diameter of Nec-1-treated mice appeared to be smaller (121.60 ± 10.40%) than the DMSO group, although the difference was not statistically significant (P = 0.1). Histologically, the aortic structure of Nec-1s-treated mice appeared normal, with continuous and organized elastin layers and rich SMCs expressing αActin. In addition, Nect-1 treatment reduced macrophage infiltration and MMP9 accumulation and increased tropoelastin and lysyl oxidase aortic levels. Together, our data suggest that pharmacological inhibition of necrosis by Nec-1 stabilizes pre-existing aneurysms by reducing inflammation and promoting connective tissue repair.

 

IQ-1S

526823 10.0mg
EUR 90

IQ-1S

B1279-25 each
EUR 548.4

IQ-1S

B1279-5 each
EUR 183.6

(1S)-Camphorsultam

C175125 1g
EUR 224
Description: 94594-90-8

NOMO-1s

ABL-TC0480 1 vial Ask for price
Description: NOMO-1s Cell Line is from human; Tissue: hemo-lymphocytic; Morphology: round; Profile: This cell line is useful for studying the differentiation and maturation of monocytes.

(1S)-(+)-Myrtenol

M125410 100mg
EUR 621
Description: 6712-78-3

(1S)-Calcitriol

T35524-10mg 10mg Ask for price
Description: (1S)-Calcitriol

(1S)-Calcitriol

T35524-1g 1g Ask for price
Description: (1S)-Calcitriol

(1S)-Calcitriol

T35524-1mg 1mg Ask for price
Description: (1S)-Calcitriol

(1S)-Calcitriol

T35524-50mg 50mg Ask for price
Description: (1S)-Calcitriol

(1S)-Calcitriol

T35524-5mg 5mg Ask for price
Description: (1S)-Calcitriol

(1S)-Chrysanthemolactone

TN2671-10mg 10mg Ask for price
Description: (1S)-Chrysanthemolactone

(1S)-Chrysanthemolactone

TN2671-1g 1g Ask for price
Description: (1S)-Chrysanthemolactone

(1S)-Chrysanthemolactone

TN2671-1mg 1mg Ask for price
Description: (1S)-Chrysanthemolactone

(1S)-Chrysanthemolactone

TN2671-50mg 50mg Ask for price
Description: (1S)-Chrysanthemolactone

(1S)-Chrysanthemolactone

TN2671-5mg 5mg Ask for price
Description: (1S)-Chrysanthemolactone

MM.1S

CSC-C9219W One Frozen vial Ask for price
Description: Leukemia - Lymphoma - Myeloma Cells

IQ-1S

abx282388-100g 100 µg Ask for price

IQ-1S

abx282388-20g 20 µg
EUR 118.75

IQ-1S

abx282388-50g 50 µg
EUR 225

Growth Medium 1S

78221 500 ml
EUR 650
Description: This liquid Growth Medium is a complete medium optimized to culture select BPS Bioscience cell lines.Optimized for Use With: CRISPRa (SAM) HeLa Cell Line (BPS Bioscience, #78193), CRISPRa (SAM) HepG2 Cell Line (BPS Bioscience, #78194)

(1S,2R)-Bortezomib

B675710 100mg
EUR 81
Description: 1132709-16-0

(1S,2S)-Bortezomib

B675715 10mg
EUR 236
Description: 1132709-14-8

(1S,3R)-ACPD

B6245-10 10 mg
EUR 350
Description: group I and II mGlu receptor agonist

(1S,3R)-ACPD

B6245-50 50 mg
EUR 1441
Description: group I and II mGlu receptor agonist

1S-cis-Bifenthrin

B382985 10mg
EUR 374
Description: 439680-77-0

(1S)-trans-Bifenthrin

B382990 10mg
EUR 1777
Description: 207347-00-0

(1S)-(+)-3-Carene

C183452 100mg
EUR 82
Description: 498-15-7

(1S)-(-)-α-Pinene

C7097-100 100mg
EUR 32

(1S)-(-)-α-Pinene

C7097-200 200mg
EUR 40

(1S)-(+)-Camphorquinone 99%

C02185 5G
EUR 378.11

(1S,3R)-RSL3

HY-100218A 10mM/1mL
EUR 180

(1S,2R)-Formoterol

F693405 100mg
EUR 11200
Description: 67346-50-3

(1S,5R)-(-)-Nopinone

N825585 100mg
EUR 1200
Description: 77982-63-9

(1S)-(-)-Alpha-Pinene

P466610 10ml
EUR 272

(1S,2S)-Bortezomib

T10061-10mg 10mg Ask for price
Description: (1S,2S)-Bortezomib

(1S,2S)-Bortezomib

T10061-1g 1g Ask for price
Description: (1S,2S)-Bortezomib

(1S,2S)-Bortezomib

T10061-1mg 1mg Ask for price
Description: (1S,2S)-Bortezomib

(1S,2S)-Bortezomib

T10061-50mg 50mg Ask for price
Description: (1S,2S)-Bortezomib

(1S,2S)-Bortezomib

T10061-5mg 5mg Ask for price
Description: (1S,2S)-Bortezomib

(1S,3R)-ACPD

T22488-10mg 10mg Ask for price
Description: (1S,3R)-ACPD

(1S,3R)-ACPD

T22488-1g 1g Ask for price
Description: (1S,3R)-ACPD

(1S,3R)-ACPD

T22488-1mg 1mg Ask for price
Description: (1S,3R)-ACPD

(1S,3R)-ACPD

T22488-50mg 50mg Ask for price
Description: (1S,3R)-ACPD